Mazdutide
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
Innovent · Phase 3 · Recruiting · Enrollment 336
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| IBI362 treatment Group | n/r | n/r | n/r | n/r | n/r |
| Placebo Control Group | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.